Abdera Therapeutics
Davide Tortora is a scientist currently working at Abdera Therapeutics since April 2024, previously serving as a research scientist at AbCellera from June 2021 to November 2023, where leadership in antibody discovery campaigns contributed to multiple presentations at significant international conferences. Tortora's academic background includes a Ph.D. in Oncology and Cancer Biology from The University of British Columbia, combined with research experience as a postdoctoral researcher and teaching assistant at the same institution, and a master's researcher role at the University of California San Diego. Educational qualifications include a Bachelor's degree and a Master's degree in Molecular Biology from Università degli Studi di Padova. Throughout a diverse research career, Tortora has engaged in significant projects related to immune evasion in cancer, CRISPR technology, and therapeutic applications in oncology.
This person is not in any teams
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.